OFIX
Orthofix Medical Inc. (OFIX) Business Model Analysis (2026)
Overall Score
Revenue Quality
Gross margin remains strong at 69.6%, supporting a solid core product economics profile.
Revenue efficiency is still acceptable with price-to-sales at 0.50x and asset turnover at 0.95x.
Profitability
Operating performance remains weak, with EBIT margin at -4.6% and net margin at -7.4%.
Returns are still negative, including ROIC at -3.5% and ROE at -14.1%, indicating the business is not yet generating attractive shareholder returns.
Cash Generation
Operating cash flow is positive, but free cash flow remains negative at -$15.5M TTM due to elevated capex.
Free cash flow yield is still negative at -6.5%, limiting near-term cash return quality.
Balance Sheet Capital Efficiency
Liquidity remains healthy with a current ratio of 2.84x and quick ratio of 1.67x.
Leverage is manageable, with debt-to-equity at 0.55x and net debt to EBITDA at 1.22x, but interest coverage is still negative at -1.22x.
Business Model Resilience
The company still shows a mixed resilience profile: strong gross margins and liquidity offset by weak profitability and negative free cash flow.
Working capital intensity remains elevated, with a cash conversion cycle of 233.7 days and inventory days of 265.7 days.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Orthofix Medical Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

